HCW Biologics Q2 EPS $(0.40) Down From $(0.12) YoY, Sales $180.41K Up From $120.41K YoY
Portfolio Pulse from Benzinga Newsdesk
HCW Biologics (NASDAQ:HCWB) reported a significant increase in quarterly losses, with EPS at $(0.40), a 233.33% decrease from $(0.12) YoY. However, sales increased by 49.84% to $180.41K from $120.41K YoY.
August 14, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HCW Biologics reported a significant increase in quarterly losses with EPS at $(0.40), a 233.33% decrease from $(0.12) YoY. However, sales increased by 49.84% to $180.41K from $120.41K YoY.
The significant increase in quarterly losses (EPS down 233.33%) is likely to negatively impact investor sentiment in the short term, despite the positive sales growth of 49.84%. The market may focus more on the increased losses, leading to a potential decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100